Details:
The BIOCAD and Shanghai Pharmaceuticals Holding joint venture has announced enrollment of patient with treatment prolgolimab in BCD-100-3/DOMAJOR clinical trial of an original anti-PD1 check point inhibitor in patients with non-small cell lung cancer (NSCLC) by BIOCAD.
Lead Product(s): BCD-100,Pemetrexed,Cisplatin
Therapeutic Area: Oncology Product Name: BCD-100
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Shanghai Pharmaceuticals Holding Co.,Ltd
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 13, 2021